Kane Biotech Inc. (CVE:KNE – Get Free Report) shares traded down 23.1% on Saturday . The stock traded as low as C$0.05 and last traded at C$0.05. 159,625 shares traded hands during trading, an increase of 120% from the average session volume of 72,560 shares. The stock had previously closed at C$0.07.
Kane Biotech Stock Down 23.1%
The company has a market capitalization of C$7.20 million, a price-to-earnings ratio of 1.25 and a beta of 0.52. The company has a quick ratio of 0.39, a current ratio of 0.80 and a debt-to-equity ratio of -331.42. The business has a 50-day moving average price of C$0.08 and a 200-day moving average price of C$0.10.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Read More
- Five stocks we like better than Kane Biotech
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Five Below Pops on Strong Earnings, But Rally May Stall
- How to Invest in Biotech Stocks
- Intel’s Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
- 3 REITs to Buy and Hold for the Long Term
- X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold Back
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
